AMPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Amphastar Pharmaceuticals Inc. (AMPH) is not a strong buy at the moment given the investor's long-term focus and beginner level. The stock has shown significant price declines (-5.29% in regular trading and -15.06% post-market), weak financial performance in Q4 2025, and insider selling activity. While the FDA approval for a new product is a positive catalyst, the overall sentiment and technical indicators suggest caution. A hold position is recommended until clearer signs of recovery or growth emerge.
The MACD is negative and expanding downward, indicating bearish momentum. RSI is at 25.528, suggesting the stock is oversold but not yet signaling a reversal. Moving averages are converging, and the price is below key support levels (S1: 26.7, S2: 26.001), further confirming a bearish trend.
FDA approval for Ipratropium Bromide HFA Inhalation Aerosol, which enhances the company's respiratory product portfolio and market potential.
Significant price drop (-5.29% regular market, -15.06% post-market). Insider selling activity increased by 4073.82% over the last month. Weak Q4 2025 financial performance with revenue, net income, and EPS all declining YoY. Analysts maintain neutral ratings with no upward price target revisions.
In Q4 2025, revenue dropped by 1.83% YoY to $183.1 million, net income declined by 35.65% YoY to $24.43 million, and EPS fell by 29.73% YoY to $0.52. Gross margin slightly improved to 46.79%, up 0.73% YoY. The company anticipates mid to high-single-digit revenue growth for 2026.
Analysts maintain neutral ratings. BofA lowered the price target to $30 from $31, citing pipeline execution risks. Barclays initiated coverage with an Equal Weight rating and a $30 price target, noting the sector's transition phase and easing pricing headwinds.
